Jared Kaltwasser

As the range of BTKi options has grown, so has the need to better understand which particular BTKi is best for a specific patient or disease state. Image Credit: Sebra – stock.adobe.com A new analysis shows how Bruton tyrosine kinase […]

Patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions who underwent 1-year fixed-duration therapy with venetoclax (Venclexta) and obinutuzumab (Gazyva) had encouraging rates of overall (OS) and progression-free survival (PFS) at 6 years, according to new data.1 The

The advent of “ultra-high-cost” treatments like gene and cell therapies will create exciting new therapies for patients, but will also likely create economic, equity, and workforce issues for health system pharmacies, a new report warns. The 2025 American Society of

The advent of “ultra-high-cost” treatments like gene and cell therapies will create exciting new therapies for patients, but will also likely create economic, equity, and workforce issues for health system pharmacies, a new report warns. The 2025 American Society of

New phase 2 data on the treatment of older patients with secondary or high-risk acute myeloid leukemia (AML) may help to clarify which patients are most likely to benefit from therapy with CPX-351.1 Writing in the journal Cancer, investigators shared

Real-world data related to the gene therapy betibeglogene autotemcel (beti-cel; Zynteglo; bluebird bio) support the therapy’s efficacy at eliminating transfusion dependence in patients with transfusion-dependent β-thalassemia. The data also suggest the therapy’s safety in a real-world setting aligns with what

Pediatric patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) may benefit from venetoclax (Venclexta), a new study suggests. The report comes from a single-center study in which 12 patients were given venetoclax-based regimens under

Provider instructions and perceived symptom improvement are among the top reasons people with pulmonary arterial hypertension (PAH) persist with taking their medications, according to a new survey. However, the survey also found that many patients get health care information from

Anatomical alterations associated with tooth loss, also known as edentulism, appear to increase the risk of obstructive sleep apnea (OSA), according to a new systematic review.1The report, which was published in Journal of Prosthodontics, found unanimous agreement on the link,

A new comparison of the safety profiles of novel targeted therapies for relapsed or refractory chronic lymphocytic leukemia (R/R CLL) suggests they all have similar—and favorable—safety profiles. The report, which was published in Therapeutic Advances in Medical Oncology, found the